Login to Your Account

Synergy shows 'Tru' value in phase III studies in IBS-C

By Marie Powers
News Editor

Tuesday, May 9, 2017

CHICAGO – After gaining approval in January for Trulance (plecanatide) to treat chronic idiopathic constipation, Synergy Pharmaceuticals Inc. wasted little time posting the complete phase III dataset on a bigger win sought in IBS-C.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription